Merck sells its biosimilars business Fresenius

Merck sells biosimilars business to Fresenius

10:11 AM, 25th April 2017
Stefan Oschmann, CEO of Merck.
Stefan Oschmann, CEO of Merck.

DARMSTADT, GERMANY: Merck said that it has sold its biosimilars business to Fresenius Kabi AG, a pharmaceutical company in Germany and a wholly owned subsidiary of the Fresenius SE & Co KGaA healthcare group.

The decision to divest biosimilars is aligned with Merck’s strategy for its healthcare business sector to focus on its pipeline of innovative medicines.

According to the terms agreed to the transaction, Merck will receive an upfront payment of €170 million, milestone payments of up to €500 million plus royalties on future product sales. The parties agreed to enter into supply and services agreements, which include drug development support and manufacturing services. The closing of the deal is expected in the second half of 2017.

The biosimilars business is part of the healthcare business sector of Merck and is located in Aubonne and Vevey in Canton de Vaud, Switzerland. The business is developing a biosimilars portfolio focused on oncology and inflammatory disorders. After completion of the transaction, the biosimilars unit will continue to operate in these locations.

“Developing and marketing innovative products and services are at the forefront of our Group strategy and all the business strategies. Today’s step reflects our ambition to resolutely continue the transformation of Merck into a science and technology company,” said Stefan Oschmann, CEO of Merck.

“The divestment of our Biosimilars business is a major step towards strategically aligning our R&D resources to Merck's healthcare priorities. We have increasing confidence in our Biopharma pipeline and this transaction will help prioritise innovative drug development of high quality and first-to-market best-in-disease assets,” said Belen Garijo, CEO, healthcare, Merck.

“With this acquisition, Fresenius Kabi enhances its position as a leading player in the injectables pharmaceutical market and further diversifies its product portfolio. The acquisition creates a platform for further growth,” added Mats Henriksson, CEO of Fresenius Kabi.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Air Products starts industrial gases plant in Guangdong, China

LEHIGH VALLEY, US: Air Products and Chemicals Inc said that it has started up another new oxygen and nitrogen plant in the Guangdong province, South C ...

Read more
Johnson Matthey opens new coatings & surface centre in US

ROYSTON, UK: Johnson Matthey’s Noble Metals team has opened a new coatings & surface solutions centre at its West Whiteland site, US. The n ...

Read more
5 European energy firms to fund Gazprom’s gas pipeline project

THE HAGUE, NETHERLANDS: Five European energy companies – Royal Dutch Shell plc (Shell), Engie, OMV, Uniper SE and Wintershall Holding GmbH have ...

Read more
Fluor bags FEED contract for BP’s offshore compression project

IRVING, US: Fluor Corporation (FLR) has been awarded a front-end engineering and design (FEED) contract by BP Trinidad and Tobago (BP), for its c ...

Read more
BASF to acquire waterproofing systems provider in US

MEXICO CITY, US: BASF has signed an agreement to acquire Grupo Thermotek, a leading waterproofing systems supplier based in Monterrey, Mexico. The dea ...

Read more
Monsanto completes $50 mn-herbicide plant expansion in US

ST LOUIS, US: Monsanto Company said that it has completed a $50 million expansion at its Muscatine plant, Iowa, US. The expansion increases the formul ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X